Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

January 24, 2024

https://www.globenewswire.com/news-release/2024/01/24/2815223/0/en/Iridex-Announces-First-Patient-Enrollment-in-MicroPulse-TLT-Clinical-Study-Conducted-in-Collaboration-with-Imperial-College-Healthcare-NHS-Trust.html

MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) — Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex’ Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research.

Read more at globenewswire.com

Related news for (IRIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.